Skin Cancer Evaluation. Simplified.

An objective, non-invasive skin cancer evaluation platform, accessible at the point of care via a handheld, point-and-click device.

DermaSensor uses light to non-invasively scan skin lesions to detect properties consistent with malignancy at a cellular and subcellular level. The intuitive handheld device provides an immediate, objective result.

Features - The Future Standard of Skin Care

Provides an instant "Investigate Further" or "Monitor" result using DermaSensor's™ proprietary algorithm
Technology has a published sensitivity of 96% for detecting skin cancer1
Wireless, ergonomically designed and easy to hold
Always on, always ready when needed

How it Works

Lesion Identification

Lesion Identification

Physician identifies the lesion of concern on their patient

DermaSensor Scan™

Physician gently touches the small device tip to the lesion, taking instance recordings at different locations of the lesion

Photo Scattering

Photon Scattering

Light reflects and scatters from particles in the cells of the skin tissue back to Dermasensor’s™ spectral sensor

Algorithmic Analysis

Algorithmic Analysis

The proprietary Dermasensor’s™ algorithm analyzes the reflected photons and provides an immediate “Investigate Further” or “Monitor” results


  • DermaSensor’s™ tip reflects and records quick bursts of light off the lesion’s cellular and sub-cellular content.
  • The light is analyzed by the built-in computer to provide information to help physicians assess skin lesions (including melanomas, squamous cell carcinomas, and basal cell carcinomas) to aid in a referral decision.
  • By examining the difference in light scattering, DermaSensor™ determines if the skin lesion is “Investigate Further” or “Monitor,” an immediate output.
  • Elastic Scattering Spectroscopy (ESS) has been validated in 30+ publications on clinical studies. Many studies have shown ESS to provide information that is comparable to histopathologic assessment in the analysis of cellular microscopic structure.2
About ESS

DermaSensor™ uses Elastic Scattering Spectroscopy (ESS), a process which evaluates how photons scatter when reflected off of different cellular structures. Malignant lesions have been reported to have different cellular and sub-cellular structures than benign lesions, scattering light differently.

For Physicians


Each year ~5,500,000 skin cancers are diagnosed in America making skin cancer more common than all other cancers combined.3 Unfortunately, only 15% of Americans report having ever been screened for skin cancer.4


While the 5-year survival rate is 98.7% for early-stage localized melanoma, it is only 24.8% for late-stage distant melanoma (metastasized to other organs).5 In addition, the total treatment costs for melanoma in situ is ~$4,648 while Stage IV melanoma is ~$159,8086.


Effective evaluation of patients with potential skin cancer in primary care is hampered by limited consultation time and limited dermatology training. PCPs will be able to use DermaSensor™ as an adjunctive tool to better assess skin lesions and determine whether additional evaluation is needed.

What is an Adjunctive Tool?

An adjunctive tool, also known as a clinical decision support tool, is not meant to replace clinicians’ decision-making. DermaSensor™ will provide clinicians with additional information about a lesion for them to consider in their referral decision. An adjunctive tool is not a diagnostic, so DermaSensor™ does not definitively determine whether or not cancer is present, specify what type of cancer may be present, nor make any decision for the user.

Why PCPs Care About Skin Cancer In Their Practice

Sunscreen suncreen man mobile
PCPs Care

1 in 5 Americans are diagnosed with skin cancer in their lifetime.3

PCPs Care

Annual cost of treating skin cancers in the U.S. is estimated at $8.1 billion, with an estimated 5.5 million new cases of skin cancer each year.3

PCPs Care

42.7% of patients present with at least one skin condition to their primary care physician.7

PCPs Care

Primary Care Physicians refer as few as 54% of the cancerous lesions they evaluate.8

As Featured In


1 Merry SP, Croghan I, McCormick B, Chatha K, Leffel D. Clinical Performance of Novel Elastic Scattering Spectroscopy (ESS) in Detection of Skin Cancer: A Blinded, Prospective, Multi-Center Clinical Trial [Initial Results]. Poster Presentation, Innovations in Dermatology Conference, Las Vegas, NV, November 3-5, 2022.

2 E Rodriguez‐Diaz, et al. Optical spectroscopy as a method for skin cancer risk assessment. Photochem and Photobiol. 2019 Nov;95(6):1441-1445.

3 “Skin Cancer Facts & Statistics.” The Skin Cancer Foundation, 31 May 2019,

4 Coups EJ et al. Prevalence and Correlates of skin cancer screening among middle-aged and older white adults in the United States Am J Med. 2010 May; 123(5): 439-445.

5 Melanoma of the Skin - Cancer Stat Facts.” SEER, National Cancer Institute, 2019,

6 RK Voss, et al. Improving outcomes in patients with melanoma: strategies to ensure an early diagnosis. Patient Relat Outcome Meas. 2015 Nov;6:229-242.

7 JL St Sauver, et al. Why patients visit their doctors: assessing the most prevalent conditions in a defined American population. Mayo Clin Proc. 2013 Jan;88(1):56-67.

8 Argenziano, G., Puig, S., Iris, Z., Sera, F., Corona, R., Alsina, M., ... & Massi, D. (2006). Dermoscopy improves accuracy of primary care physicians to triage lesions suggestive of skin cancer. Journal of Clinical Oncology, 24(12), 1877-1882.

80-0009.1 v2

Scroll to Top